ClinicalTrials.gg
Status unknownNCT01711073Updated Jan 24, 2013

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease

A Phase 1 interventional study of Mobilization with G-CSF and Mozobil in End Stage Liver DIsease, sponsored by Proteonomix, Inc.. Status unknown at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-01-24.

Sponsored by Proteonomix, Inc. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies in End Stage Liver Disease with a site in United States — 9 open to participants now, 15 under way, none of them phase 3. End Stage Liver Disease · United States.

Planned enrollment
36th of 48
15 · median 64
Started
2012
with 2 others
Phase 1
5 of 66
1 open now
Registered
20th of 66
by date

Among the 66 studies in End Stage Liver Disease with a site in United States, this one is the 36th largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2012, is one of 5 in phase 1, and was the 20th registered.

End Stage Liver Disease

155 studies on the registry are indexed under End Stage Liver Disease; 31 are open to participants now.

Browse End Stage Liver Disease studies →

Open to participants now

9 of the 66 studies in End Stage Liver Disease with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 End Stage Liver Disease studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in End Stage Liver Disease with a site in United States, or all of them as a file.
02

Study summary

A phase I trial to study the safety of mobilization of stem cells with G-CSF and Mozobil in patients with chronic liver disease.

Read the detailed description

Liver cirrhosis in humans represents the end stage of chronic liver injury. Supply of "new" stem cells to the liver could regenerate hepatocytes and restore the lost function. Delivery of Mesenchymal Stem Cells (MSCs) has been shown in animal models and limited clinical trials to result in improved liver disease (MELD) score.

In preclinical studies we have demonstrated that the combination of G-CSF plus Mozobil can effectively mobilize both hematopoietic stem cells (HSCs) and MSCs into the peripheral circulation. While G-CSF only mobilizes HSCs.

The clinical trial will test the safety of treating patients with end stage liver disease with G-CSF and Mozobil to mobilize MSCs into the peripheral circulation.

03

Conditions studied

  • End Stage Liver DIsease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a clinical diagnosis of cirrhosis Age greater than or equal to 18 years MELD score less than or equal to 12 able to provide and seronegative count >50,000, WBC count > 2,000 No history of within the last 5 years, except for non-melanoma skin cancer or cervical carcinoma in situ No lesions suspicious for liver cancer on CT and/or MRI within prior 4 months

Exclusion criteria

Exclusion Criteria:

Patients with acute or subacute onset of liver disease Patients who have received a liver transplant Age \< 18 MELD score >12 Patients whose MELD scores are currently less than or equal to 12 but with history of prior deterioration with MELD score >12 Unable to provide Patients with or seropositivity Pregnant or lactating females Enrolled in another research protocol Any condition that precludes serial follow up Patients with history of within the last 5 years, except for non-melanoma skin cancer or cervical carcinoma in situ Any lesions suspicious for liver cancer on CT and/or MRI within prior 4 months Patients with palpable splenomegaly on physical examination ANy condition that in the investigators opinion would likely increase the risk of particpation or would likely confound interpretation of the data

-

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Mobilization with G-CSF plus Mozobil

    Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)

    Drug: Mobilization with G-CSF and Mozobil

Interventions

  • DrugMobilization with G-CSF and Mozobil

    Drug page: Filgrastim

    Treatment with drugs for mobilization of MSCs

    Also known as: Filgrastim, Neupogen, Plerixafor, AMD3100

06

What researchers measure

Primary outcomes

  1. Toxicity as measured by bone pain, hematologic parameters, GI measures and renal parameters

    The primary end point for this study is the safety of mobilization of stem cells in patients with end stage liver disease. Adverse events will be documented to assess safety.

    Time frame: 12 months

Secondary outcomes

  1. Effects of Mobilization

    The secondary objective is to study the mobilization of stem cells, including MSCs, to the peripheral circulation and the effect on liver function. Functional assays will define the levels of heamtopoietic stem cells (CD34+ cells) and MSCs (CFU-F) in the circulation of patients.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • University of Medicine and Dentistry of New Jersey
    Newark, New Jersey 07101, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2012
First posted
Oct 22, 2012
Start
Oct 2012
Primary completionEst.
Sep 2013
CompletionEst.
Sep 2013
Last update
Jan 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01711073
Lead sponsor
Proteonomix, Inc.
Responsible party
Sponsor
First posted
Oct 22, 2012
Start date
Oct 2012
Primary completion
Sep 2013 (estimated)
Completion
Sep 2013 (estimated)
Last update
Jan 24, 2013

Study contacts

Baburao Koneru, MD
principal investigator · University of Medicine and Dentistry of New Jersey

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion